Asimov Press β’ 754 implied HN points β’ 11 Mar 26
- AI models now let researchers design antibody binders on the computer, greatly reducing the experimental search effort needed to find promising candidates.
- There is a practical five-step pipeline β pick a target, prepare or predict its structure, run design tools, filter candidates, and validate in the lab β which uses public tools but typically costs thousands of dollars.
- Design success is highly target-dependent and improving affinity, specificity, and drug-like properties remains difficult and costly, but AI makes it realistic to engineer more complex, multi-property binders going forward.